#United States #Dublin #Lenire #Neuromod Devices #Tinnitus Treatment

Lenire's Inclusion in U.S. Clinical Guidelines for Tinnitus

In a groundbreaking move, the American Academy of Otolaryngology – Head and Neck Surgery Foundation (AAO-HNSF) has officially included Lenire, a bimodal neuromodulation device, in its Clinical Practice Guidelines for tinnitus. This inclusion marks the first significant addition to the Academy's guidelines since they were first established in 2014. As the only FDA-approved bimodal neuromodulation treatment device, Lenire is poised to revolutionize the management of tinnitus in the United States.

A New Era for Tinnitus Treatment

The AAO-HNSF's guidelines are crucial for otolaryngologists (ENTs) across the country, offering evidence-based recommendations to enhance patient care. The decision to incorporate Lenire not only underscores its effectiveness but also highlights the growing recognition of bimodal neuromodulation as a legitimate treatment option. This is particularly relevant given the millions of Americans who suffer from tinnitus, a condition characterized by persistent ringing or noise in the ears.

As Dr. Ross O'Neill, Founder and CEO of Neuromod Devices, states, “This is another historic first for our company, our technology, and the field of tinnitus treatment.” With this new guideline, more than 12,000 ENTs in the U.S. now have access to a safe and effective treatment to recommend to their patients.

Understanding Lenire and Its Mechanism

Lenire works by combining sound stimulation with mild electrical impulses delivered to the surface of the tongue, a technique referred to as bimodal neuromodulation. The therapy aims to provide relief from the distressing symptoms of tinnitus. Robust clinical evidence supports Lenire's safety and efficacy, with results from three large-scale clinical trials demonstrating its potential to significantly reduce tinnitus symptoms.

The pivotal TENT-A3 trial was instrumental in securing Lenire's FDA approval in 2023, and subsequent real-world studies have reinforced its effectiveness. Reports indicate that up to 91.5% of patients experience a clinically significant reduction in their tinnitus symptoms after treatment. Such compelling outcomes are expected to foster trust among healthcare providers and patients alike.

Real-world Evidence and Acceptance

The growing body of real-world evidence surrounding Lenire is a testament to its impact. Clinical findings have been published in reputable journals, with studies documenting significant reductions in tinnitus among patients treated with the device. For example, data published in the American Journal of Audiology revealed that 81.8% of patients with bothersome tinnitus reported improvements after using Lenire.

As the Clarion Call for Improved Treatments Resounds, reliance on rigorous, clinical evidence is imperative. The inclusion of bimodal neuromodulation in the AAO-HNSF guidelines reflects a shift toward more holistic and scientifically grounded approaches to patient care. Neuromod is committed to expanding the scope of research and support to ensure Lenire is an accessible treatment for tinnitus patients not only in the U.S. but globally.

Availability and Future Prospects

Lenire is currently available through qualified healthcare professionals in the U.S., Canada, Europe, and Australia. It is also recognized as a treatment option within the U.S. Veterans Affairs system, allowing a broader range of patients access to this innovative therapy. Neuromod's future plans include continued partnerships with clinicians to further establish Lenire as the leading standard of care for tinnitus management worldwide.

In summary, the incorporation of Lenire into the U.S. Clinical Practice Guidelines for tinnitus marks a significant milestone in the evolution of tinnitus treatment. With its robust scientific backing and commitment to improving patient outcomes, Lenire stands as a beacon of hope for millions experiencing the challenges of tinnitus.